Q3 Earnings Estimate for Prenetics Global Issued By Sidoti

Prenetics Global Limited (NASDAQ:PRE) – Analysts at Sidoti lowered their Q3 2026 EPS estimates for Prenetics Global in a report released on Wednesday, July 15th. Sidoti analyst A. Hantman now expects that the company will post earnings of ($0.85) per share for the quarter, down from their previous estimate of ($0.48). The consensus estimate for Prenetics Global’s current full-year earnings is ($1.26) per share. Sidoti also issued estimates for Prenetics Global’s Q4 2026 earnings at ($0.95) EPS, Q1 2027 earnings at ($0.51) EPS, Q2 2027 earnings at ($0.25) EPS, Q3 2027 earnings at ($0.01) EPS, Q4 2027 earnings at $0.16 EPS and FY2027 earnings at ($0.60) EPS.

Prenetics Global (NASDAQ:PRE) last announced its earnings results on Wednesday, June 10th. The company reported ($0.56) EPS for the quarter, missing the consensus estimate of ($0.49) by ($0.07). Prenetics Global had a negative net margin of 62.45% and a negative return on equity of 20.33%. The company had revenue of $35.95 million for the quarter, compared to analysts’ expectations of $36.00 million.

Several other brokerages also recently commented on PRE. Weiss Ratings restated a “sell (d-)” rating on shares of Prenetics Global in a research report on Tuesday, April 21st. Benchmark boosted their target price on shares of Prenetics Global from $30.00 to $40.00 and gave the company a “buy” rating in a research note on Wednesday. Four equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $34.25.

Prenetics Global Trading Down 3.3%

NASDAQ PRE opened at $18.29 on Friday. Prenetics Global has a 1 year low of $7.18 and a 1 year high of $23.63. The stock’s 50-day moving average price is $18.70 and its two-hundred day moving average price is $18.47. The company has a market cap of $308.55 million, a PE ratio of -3.99 and a beta of 0.26.

Institutional Trading of Prenetics Global

Hedge funds and other institutional investors have recently modified their holdings of the company. 683 Capital Management LLC acquired a new stake in Prenetics Global during the fourth quarter valued at $1,181,000. T3 Companies LLC acquired a new position in Prenetics Global in the 4th quarter worth about $170,000. Kingsview Wealth Management LLC acquired a new position in Prenetics Global in the 4th quarter worth about $172,000. Stevens Capital Partners raised its stake in shares of Prenetics Global by 4.7% during the 4th quarter. Stevens Capital Partners now owns 18,207 shares of the company’s stock worth $287,000 after purchasing an additional 825 shares in the last quarter. Finally, JPMorgan Chase & Co. purchased a new stake in shares of Prenetics Global during the 3rd quarter worth about $65,000. 25.01% of the stock is currently owned by hedge funds and other institutional investors.

Prenetics Global News Roundup

Here are the key news stories impacting Prenetics Global this week:

• Positive Sentiment: Prenetics said its IM8 business secured $1 billion in non-dilutive financing, which could support growth without issuing new shares and signals strong outside confidence in the subsidiary’s outlook. Prenetics’ IM8 Secures $1 Billion Non-Dilutive Financing as Revenue Outlook Rises
• Positive Sentiment: Management also highlighted that PRE continues to exceed expectations and is receiving preferential financing, reinforcing the idea that the company may have better operating momentum than the market had assumed. PRE Continues to Exceed Expectations and Receive Preferential Financing
• Positive Sentiment: CEOs comments about using the financing to fuel IM8’s growth suggest the company has a clearer path to scaling a high-growth subsidiary, which can improve investor sentiment around future revenue expansion. Prenetics CEO on securing 1 billion funding to fuel subsidiary IM8’s growth
• Neutral Sentiment: Sidoti and other analysts maintained a generally constructive stance overall, with a consensus recommendation of “Moderate Buy,” but the reports mostly focused on model updates rather than a major new catalyst. Prenetics Global Limited (NASDAQ:PRE) Given Consensus Recommendation of Moderate Buy by Analysts
• Negative Sentiment: Sidoti cut earnings estimates for several periods, including 2026-2027 quarters and FY2027, which could weigh on the stock because it implies weaker near-term profitability than previously expected.

About Prenetics Global

Prenetics Global (NASDAQ: PRE) is a molecular diagnostics and genetic testing company that delivers a broad range of laboratory and at-home testing solutions. The company’s core offerings include next-generation sequencing (NGS) panels for hereditary health risks, pharmacogenomic reports to guide medication choices, and comprehensive consumer DNA testing services. In addition to genetic insights, Prenetics provides infectious disease diagnostics—most notably real-time PCR testing for pathogens such as SARS-CoV-2—through an integrated platform that combines sample collection, laboratory processing and digital reporting.

Serving both business-to-consumer and business-to-business markets, Prenetics operates a network of laboratories and service centers across Asia Pacific, Europe, the Middle East and North America.